Status:
UNKNOWN
Influence of Glucagon Inhibition in Relation to the Anti-Diabetic Effect of Glucagon-Like Peptide-1 (GLP-1) in Patients With Type 2 Diabetes Mellitus
Lead Sponsor:
University Hospital, Gentofte, Copenhagen
Collaborating Sponsors:
University of Copenhagen
Hvidovre University Hospital
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Incretinbased treatment of patients with type 2 diabetes mellitus (T2DM) has increasing interest. The incretin glucagon-like peptide-1 (GLP-1) stimulates beta-cells to increased secretion and producti...
Eligibility Criteria
Inclusion
- Type 2 Diabetes Mellitus according to criteria from WHO
- Normal hepatic and kidney function
- No overt diabetic complications
- Treatment with insulin or glitazones
- Informed consent
Exclusion
- BMI \< 23
- BMI \> 35
- HbA1c \> 10%
- Pregnancy
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2009
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00655603
Start Date
March 1 2008
End Date
September 1 2009
Last Update
April 6 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.